Dermatology News

The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the biologic product, according to a company press release.

Patients with psoriasis are increasingly linked to risks for Crohn’s disease, ulcerative colitis and a combination of the two diseases, according to a review study published in JAMA Dermatology.

A smartphone app may help medical students more accurately differentiate melanomas from benign skin lesions, according to study results published in JAMA Dermatology.

Today, the FDA gave tentative approval to Bryhali lotion, 0.01%, for treating plaque psoriasis topically in adult patients, according to a press release.

An online, collaborative connected-health model yielded many results that were statistically identical to adults receiving in-person care for their psoriasis, according to findings published in JAMA Network Open.

The FDA has approved Nuzyra for treating adults with community-acquired bacterial pneumonia and acute skin and skin structure infections, according to Paratek Pharmaceuticals.

Today, the FDA approved Seysara to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older, according to a press release issued by the drug manufacturer.

Acupuncture was one of several complementary and alternative therapies that benefited patients with psoriasis, according to a systematic review recently published in JAMA Dermatology.

The FDA has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes of Xolair as additional formulations for patients with allergic asthma and chronic idiopathic urticaria, according to press releases from Genentech and Novartis.

Bone erosions are more dependent on a patient’s age and are enhanced in psoriatic arthritis, whereas enthesiophytes are more dependent on disease duration and are severe in both psoriasis and psoriatic arthritis, according to findings published in Arthritis Research & Therapy.